Reports Q4 revenue $700K, consensus $1.09M…”2023 was a transformative year for Revolution Medicines and our pioneering RAS(ON) inhibitors. We showed that both RMC-6236 and RMC-6291 as single agents can deliver clinically meaningful antitumor responses at doses that are generally safe and well tolerated, results we believe provide broad clinical validation of our RAS(ON) inhibitor portfolio,” said Mark A. Goldsmith, M.D., Ph.D., chief executive officer and chairman of Revolution Medicines. “With a year-end cash and investments balance of $1.85 billion after acquiring EQRx, we are well capitalized to execute exciting plans this year and beyond to advance our compelling development-stage pipeline, aiming to change the treatment landscape for patients living with RAS-addicted cancers.”
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on RVMD:
- Revolution Medicines Reports Fourth Quarter and Full Year 2023 Financial Results and Update on Corporate Progress
- RVMD Upcoming Earnings Report: What to Expect?
- Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2023 After Market Close on February 26, 2024
- Revolution Medicines to Participate in Upcoming Investor Conferences
- Carnival upgraded, PayPal downgraded: Wall Street’s top analyst calls
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue